Evidence map›Paper›PMID 39167921›Full record

ArticleACS nano2024

Donepezil Nanoemulsion Induces a Torpor-like State with Reduced Toxicity in Nonhibernating

Maria Plaza Oliver, Erica Gardner, Tiffany Lin, Katherine Sheehan, Megan M Sperry, Shanda Lightbown, Manuel Ramsés Martínez, Daniela Del Campo, Haleh Fotowat, Michael Lewandowski and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Maria Plaza OliverWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Erica GardnerWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Tiffany LinWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Katherine SheehanWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Megan M SperryWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Shanda LightbownWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Manuel Ramsés MartínezWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Daniela Del CampoWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Haleh FotowatWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Michael LewandowskiWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Takako TakedaWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Alexander C PauerWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Shruti KaushalWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Vaskar GnyawaliWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Maria V LozanoDevelopment and Evaluation of Nanodrugs (DEVANA) Group, Faculty of Pharmacy and Biomedicine Institute at University of Castilla-La Mancha, 02008 Albacete, Spain.ORCID 0000-0001-7774-732X
Manuel J Santander OrtegaDevelopment and Evaluation of Nanodrugs (DEVANA) Group, Faculty of Pharmacy and Biomedicine Institute at University of Castilla-La Mancha, 02008 Albacete, Spain.
Richard NovakWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Michael SuperWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.
Donald E IngberWyss Institute for Biologically Engineering at Harvard University, Boston, Massachusetts 02215, United States.ORCID 0000-0002-4319-6520

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Achieving a reversible decrease of metabolism and other physiological processes in the whole organism, as occurs in animals that experience torpor or hibernation, could contribute to increased survival after serious injury. Using a Bayesian network tool with transcriptomic data and chemical structure similarity assessments, we predicted that the Alzheimer's disease drug donepezil (DNP) could be a promising candidate for a small molecule drug that might induce a torpor-like state. This was confirmed in a screening study with

Indexed as

DonepezilEmulsionsLarvaXenopus laevisAnimalsNanoparticlesParticle SizeDonepezilEmulsionsdonepezilnanoemulsiontadpolestorporXenopus laevis

Identifiers

PMID39167921
PMCPMC11375763

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.